Technology-Intensive Improvements by SCHOTT in Hungary

25-year-old SCHOTT Hungary, owned by the German Carl Zeiss Foundation, is launching an investment project on its site in Lukácsháza, W Hungary.

A report by the Hungarian Investment Promotion Agency says that 16 items of highly-automated, new generation, Industry 4.0 production lines will be put in service in the pharmaceutical glass and packaging material manufacturing unit. This will be financed from EUR 41 million, together with the establishment of a production and service building.

SCHOTT Hungary Kft is a key plant in Hungary, producing primary pharmaceutical glass packaging materials. The company started its operation in Lukácsháza 25 years ago, and has been producing high quality packaging materials for the pharmaceutical industry ever since. In the pharmaceutical sector the Hungarian unit is considered to be the largest manufacturing plant of the Mainz-based SCHOTT group, which is solely owned by the Carl Zeiss Foundation.

This investment on the Hungarian site will involve the purchasing of 16 highly automated production lines, which will be equipped with advanced, energy efficient, high speed and highly automated, new generation measuring and IT devices. An appropriate hall will also be built to accommodate the technology.

The hundreds of millions of vials and capsules, which constitute the annual output of these new production lines, will be distributed to all major pharmaceutical companies in Europe, in order to enable the safe use of any vaccine or medicine filled into them. The SCHOTT products will among others store and contain the vaccine against COVID-19.